![](/wp-content/uploads/2018/10/XvtRRehaQbqcLCuuwsFq.png)
$599
Omnipod Approved to use Novo’s Fiasp; Senseonics Now Covered on Humana
Insulet announced it has received 510(k) clearance to use Novo’s Fiasp in Insulet’s Omnipod patch pump. Recall, earlier this week, Novo announced it received FDA approval for Fiasp pump compatibility in adult patients requiring insulin therapy. Additionally, Senseonics announced that Humana will now be providing coverage for the Eversense implantable CGM system and insertion procedure (effective October 22, 2019). Below, FENIX provides brief thoughts and potential market implications for each news item.